Introduction
• HPA Axis controls thyroid release (TRH --> TSH --> Thyroxine (T4) and Tri-iodothyronine (T3))
• Thyroid produces T4, and small amount of T3
• 85% of biologically active T3 produced by extra-thyroidal peripheral conversion by 5'-deiodinaze enzymes (mainly liver and kidneys).
• Most patients with thyroid dysfunction have normal HPA axis, and have abnormal TSH.
• Very rarely, patient may have thyroid disease mediated by HPA • Thyroid produces T4 and T3, but 85% of body's T3 is created by extra-thyroidal conversion
• T4-->T5 by 5′-deiodinase enzymes made in liver and kidney • Only small unbound T4/T3 is biologically active (free T4/T3).
• Rest is bound to thyroxine-binding globulin (TBG) and to less extent transthyretin and albumin.
• When bound = Inactive, act as a storage reservoir.
• Iodide is required for thyroid synthesis (In US iodide deficiency is very rare)
Definitions
• Subclinical thyroid dysfunction defined as:
• Elevated or low Thyroid-Stimulating Hormone (TSH) (normal ref: 0.45-4 .50 mIU/L) in the setting of normal thyroid levels.
• Overt Thyroid Disease
• Presence of abnormal thyroid hormone (free thyroxine +/-triodothyronine) levels.
• Hyperthyroidism
• Primary: TSH is low due to negative feedback of high levels of circulating T3 and T4
• Secondary: TSH is increased with increased T4/T3 levels.
• Hypothyroidism
• Primary: TSH is high due to low T4/T3 levels.
• Secondary: TSH is low or normal with variable response to TRH (depending on lesion site -pituitary or hypothalamic).
• Euthyroid Sick Syndrome [MKSAP]
• During recovery phase of severe illness (from non-thyroidal illness) can alter the results of thyroid function tests.
• This is called "euthyroid sick syndrome", which is more common in critically ill patients.
• Mechanisms are unknown, likely reated to cytokine release.
• Serum TSH level is not expected to increase to greater than 10 microunits/mL (10 milliunits/L), except perhaps in the recovery phase of a serious illness.
• 
Thyrotoxicosis Hypothyroidism

Graves
Amiodarone Induced Thyroid Dysfunction
• Type 1
• Thyroid is abnormal -typically patients have previous thyroid disease -predisposed to hyperthyroidism.
• Extra iodine load from amiodarone causes increase in thyroid hormone production causing thyrotoxicosis.
• Order thyroid ultrasound: Will have increased sized, hypervascularity, etc..
• Jod-Basedow phenomenon (vs. Wolff-Chaikoff effect which is opposite) • Type 2
• Thyroid is previously normal.
• Amiodarone causes thyroiditis -inflammation causing a release of • Stores thyroid hormone in thyroid gland, released.
• Can be elevated in hyperthyroidism and destructive thyroiditis • Decreased if patient taking exogenous thyroid hormone.
• Followed post resection or ablation in well-differentiated thyroid cancer (papillary or follicular thyroid cancer) ▪ Good tumor marker, used to detect cancer recurrence or persistence ▪ Should be absent post-thyroidectomy • Should also measure serum anti-thyroglobulin levels (if present, can falsely drop thyroglobulin levels) • Calcitoinin
• Secreted by C-cells (of thyroid gland).
• Routine measurement is not recommended (only recommended in "high risk" groups for medullary ca): ▪ Indications: family hx of medullary thyroid cancer, MEN-2, or biopsy suggestive of medullary ca.
• Tumor marker for medullary thyroid cancer • Radioactive Iodine Uptake (RAIU)
• Measures iodine uptake over time period (4 and 24hrs after iodine injestion).
• Thyrotoxicosis pts (hyperthyroidism) have elevated >30% @24hrs, or high-normal RAIU ▪ Indicates endogenous production of thyroid hormones.
• Decreased in:
▪ Subacute, silent or post-partum thyroiditis ▪ Exposure to exogenous thyroid hormones • Increased (Homogeneous) in:
▪ Toxic multinodular goiter
Thyroid Disease
Diagnostic Tests
▪ Pregnacy ▪ Breastfeeding ▪ (Postpartum thyroiditis occurs in 1/3 of women with elevated thyroid peroxidase ab level).
Imaging
• Normal gland size 15-20g.
• Ultrasound • Measure size of gland.
• Solid vs. cystic nodule.
• Facilitate fine needle aspiration biopsy (FNAB) • Radioisotope scan (Technetium-99)
• Test of Structure -Order if thyroid nodule in a patient who is hyperthyroid with low TSH • Differentiates between hot (excess hormone) and cold (non-functioning) nodules. ▪ Hot nodule --> Very low malignancy risk; treat hyperthyroidism. ▪ Cold nodule --> ~5% chance of malignancy; further workup (U/S, FNAB) • Radioactive iodine uptake (RAIU)
• Test of Function -order if thyrotoxic.
• Measure iodine turnover in vivo.
• If increased uptake (Radioiodine incorporated) --> gland is overactive (hyperthyroid)
• If decreased uptake (not incorporated) --> gland is leaking thyroid hormone (thyroiditis), exogenous thyroid hormone use, excess iodine intake (amiodarone, contrast dye).
• Thyroid Biopsy
• Fine need aspiration (FNA) for cytology differentiates between benign and malignant disease.
Thyrotoxicosis Graves Disease
• Most common cause of thyrotoxicosis, any age 3-4th decades peak.
• Familial (15% have close family member w/ Graves, 50% have family with positive antibodies)
• B-cells produce Thyroid Stimulating Immunoglobulin (TSI), binds TSH receptor, stimulates thyroid gland.
• Can be triggered by:
• Ophthalmopathy is common (Increased tissue volume due to inflammation and accumulation of glycosaminoglycans, stimulated by TSI, increase osmotic pressure in orbit, displacing eye forward).
• Opthalmopathy (5-10% of Graves)
▪ Varies Mid-to-Severe ▪ Lid Changes: Proptosis, Exopthalmos, ▪ Inflammation: Chemosis, Conjunctival Injection, Periorbital Edema, Iritis ▪ Extraocular: Double Vision ▪ Optic Nerve Compression: Visual Acuity (Blindness) • Either hypothyroidism or hyperthyroidism can make ophthalmopathy worse! • Dermopathy: cutaneous glycosaminoglycan deposition.
• Diagnosis:
• Low TSH, Increased free T4 (and/or increased T3)
• POSITIVE for TSI • Increased radioactive iodine uptake. ▪ (Diffuse high uptake on thyroid scan [ONLY do this if nodule is present!]).
• Treatment
• See "Treatments".
• Often PTU or Methimazole (Methimazole preferred, but careful with BM suppression). ▪ Treat until remission (20-40% achieve spontaneous remission at 6-18mo of treatment). ▪ Small goitre and recent onset are good indicators for long-term remission with medical therapy.
• B-blockers for symptoms.
• Radioactive Iodine Ablation 131I if PTU or MMI trial does not produce remission.
▪ MAINSTAY!! (PREFERRED) ▪ However, contraindicated in pregnancy, and DO NOT do if ophthalmopathy is present ▪ Often became hypothyroid requiring lifetime supplementation. 
Subacute Thyroiditis (Thyrotoxic Phase)
• Acute inflammatory disorder of the thyroid gland leading to initial thyrotoxic state and later on hypothyroidism, and eventually by euthyroidism in most cases.
• Categorized as Painful or Painless • Inflammation causes disruption of thyroid follicles, leading to thyroid hormone release (NOT production). ▪ Therefore, Radioactive Iodine Uptake will be negative.
• Types:
• Painful -▪ Viral (usually preceeded by URTI), ▪ De Quervain's (Granulomatous Thyroiditis) -acute anterior neck pain. Viral illness preceeding months. CT: patchy infiltrate, minimal lymphadenopathy • Painless -postpartum, auto-immune, lymphocytic.
▪ Occurs in 5-10% of postpartum women, but only symptomatic in 1/3. • Diagnosis
• Elevated T4, T3, low TSH, RAIU reduced.
Thyroid Disease Thyrotoxicosis
• ESR elevation • (Rise in RAIU reflects gland recovery) • Treatment
• Painful -high dose NSAIDs, sometimes prednisone • Iodinated contrast agents (iopanoid acid, ipodate) -inhibit peripheral conversion T4 to T3
• B-blockers usually effective for hypermetabolic and cardiac symptoms.
• (If hypothyroid -treat with thyroxine.)
Toxic Adenoma/Toxic Multinodular Goitre
• Functioning adenoma that is hypersecreting T3/4 • Can be:
• Single: toxic adenoma • Multiple: Toxic Multinodular goitre (aka Plummer's disease).
• Classically seen in ederly people presenting with Afib (later find other hyperthyroid features).
• Diagnosis
• Low TSH, high T3/4
• Thyroid Scan (increased uptake in nodule(s), and remainder of gland is suppressed.
• Treatment
• PTU or MMI (make euthyroid)
• Definitive: ▪ If PTU/MMI fail: Radioactive iodine to ablate tissues. ▪ Sometimes surgery also used, but rarely.
Thyrotoxic Crisis/ Thyroid Storm
• Acute exacerbation of all hyperthyroid symptoms presenting in life-threatening state.
• Rare, medical emergency, mortality 20-30%.
• Often precipitated by trauma/infection/surgery in pts who are already hyperthyroid.
• Symptoms:
• Hyperthyroid symptoms, but also tachyarrhythmias, hepati failure + jaundice, confusion, CHF, shock.
• Increased T3/4, undetectable TSH • +/-: Anemia, WBC, hyperglycemia, hypercalcemia, elevated LFTs.
• Treatment
• Supportive: fluids, electrolytes, diuretics, vasopressors, cooling blanket, tylenol for hyperthermia.
(NOTE: LOTS of fluids! usually patients lose a lot through vomiting, diarrhea, insensible) • Propranolol IV for tachycardia and to decrease T4-->T3 conversion.
(1mg IV q5min until desired effect, PO 20-120mg q6h) • Methimazole ▪ Preferred -causes rapid decline in thyroxine levels, less S/E ▪ Start 10-30mg daily OR:....
• Propylthiouracil
▪ Starting dose 75-100mg q8h ▪ Drug-induced agranulocytosis (limited popularity of this drug) • Iodide (NaI, KI, Lugol's solution): inhibit thyroid hormone release after PTU given ▪ Orally as Lugol's Solution (4 drops q12h) or IV as sodium iodide (500-1000mg q12h) ▪ If Iodide allergy: Lithium (300mg PO q8h can be used) • Hydrocortisone (300mg IV load then 100mg IV q8h) ▪ Thyroid storm can accelerate glucocorticoid metabolism, often get adrenal insufficiency.
• Iodinated radiocontrast solutions (iopanoic acid) to stop peripheral conversion and T3/4 release.
• Lithium: inhibits T3/4 release.
• Dexamethasone to block peripheral conversion, lower body temp, treat underlying autoimmune condition.
• Plasmapheresis/Dialysis: IF EXTREME, to remove high T3/4.
Treatments
• Antithyroid drugs
• Thionamides ▪ Inhibit thyroid hormone synthesis by inhibiting peroxidase-catalyzed reactions. Inhibit organification of iodine, blocking coupling of iodotyrosines.
▪ PTU also inhibits peripheral deiodination of T4 to T3.
▪ propylthyouracil (PTU) ▪ methimazole (MMI) (for Graves) ▪ MMI is preferred over PTU due to longer duration of action (once daily), more rapid efficacy, less side-effects. ▪ MMI is contraindicated in pregnancy.
▪ CAUTION: induce permanent remission in 20-30% of patients with Graves.
▪ Can create euthyroid state before definitive management. ▪ Adverse effects: rash, teratogenicity, hepatitis?, agranulocytosis, hepatotoxicity, ANCApositive vasculitis.
• B-blockers for symptom control.
• Radioactive iodine ablation (for Graves).
• Surgery (hemi, subtotal, complete thyroidectomy)
Hypothyroidism
• Common (2% women vs. 0.2% men) • Causes:
• Hashimodo Thyroiditis (most frequent)
• Iatrogenic Hypothyroidism (After ablation, external beam to thyroid, surgical removal)
▪ Thyroid Agenesis ▪ Dyshormonogenesis (genetic defect) • Celiac Disease (poor L-thyroxine absorption -> may require higher doses)
Sx / Px
• Symptoms • Not one in particular diagnostic (look at all symptoms)
• Fatigue! / Reduced Endurance
• Vitals: • Ultrasound (May have nodules to biopsy)
Treatment
• Oral levothyroxine is mainstay (daily dose of 50-200 mcg)
• Take on empty stomach (1hr before or 2-3hr after food or calcium/iron containing supplements)
• Initial dose is 50 mcg/day, increased in 50 mcg/day increments q3-5w until TSH level normalizes (usually 100-200 mcg/day) • Target TSH 0.5-4.3 mU/L ▪ Patients >80 --> Can use higher range (i.e. 1-7 mU/mL) • IV levothyroxine used initially for severe hypothyroidism (reduced GI absorption of PO meds)
• Initial dose: 250 mcg on 1st day, then 100 mcg on 2nd day, 50 mcg daily until oral therapy possible.
• Liothyronine & combinations of T3/T4 therapy --> Most evidence shows no benefit over traditional
• T3 has very short thalflife, causes spikes to T3 (concern for cardiac pts).
Subclinical Hypothyroidism
• TSH is above normal, and T3/T4 normal.
• VERY COMMON • Mild or no symptoms of hypothyrodism • Causes (The same as overt)
• Labs:
• Mild elevation in total cholesterol, LDLC, CRP. • Meta Analysis: Increased risk of atherosclerosis and cardiac events
• Minimal evidence that L-thyroxine improves these outcomes when TSH < 10 • When to treat?
• TSH 5-10 --> Unclear (may treat if symptomatic)
• TSH > 10 --> Treat (clear benefit)
• Indication for Treating Subclinical Hypothyroidism ▪ TSH > 10 ▪ Elevated TSH > ULN and: ▪ Markedly symptomatic ▪ If pregnant OR Planning pregnancy ▪ Goitre ▪ Positive Anti-TPO antibodies
•
Hypothyroidism in Elderly
• The effects appear to be different in older patients.
• >70yo do not experience mortality benefit of 40-70yo for treating subclinical hypothyroidism (above). ▪ Some emerging studies that subclinical hypothyroidism can be protective in older patients: ▪ (Gussekloo et al. 2004 JAMA) ▪ Followed 599pts 85years to 89 years. ▪ Plasma TSH and free thyroxine were not associated with disability, depression, cognitive impairment. ▪ Increasing TSH levels are associated with lower mortality rate. ▪ Less mortality in higher TSH levels (2.71 mIU/L assocated with 0.77 hazard ratio of death [0.63-0.94 ].
• Patients to that live to 100 (centenarians) have slightly higher TSH levels.
• Other studies propose similar associations....
• May change reference range in pts > 80yo to 1-7mU/mL
